Medmira Stock Current Valuation
| 47M Stock | EUR 0.05 0 5.75% |
Valuation analysis of MedMira helps investors to measure MedMira's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that MedMira's price fluctuation is out of control at this time. Calculation of the real value of MedMira is based on 3 months time horizon. Increasing MedMira's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MedMira stock is determined by what a typical buyer is willing to pay for full or partial control of MedMira. Since MedMira is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MedMira Stock. However, MedMira's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.046 | Real 0.0436 | Hype 0.05 | Naive 0.043 |
The real value of MedMira Stock, also known as its intrinsic value, is the underlying worth of MedMira Company, which is reflected in its stock price. It is based on MedMira's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of MedMira's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of MedMira helps investors to forecast how MedMira stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MedMira more accurately as focusing exclusively on MedMira's fundamentals will not take into account other important factors: MedMira Company Current Valuation Analysis
MedMira's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current MedMira Current Valuation | 34.88 M |
Most of MedMira's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedMira is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, MedMira has a Current Valuation of 34.88 M. This is 99.76% lower than that of the Healthcare sector and 99.25% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 99.79% higher than that of the company.
MedMira Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedMira's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MedMira could also be used in its relative valuation, which is a method of valuing MedMira by comparing valuation metrics of similar companies.MedMira is currently under evaluation in current valuation category among its peers.
MedMira Fundamentals
| Return On Asset | -0.23 | |||
| Profit Margin | (2.27) % | |||
| Operating Margin | (1.79) % | |||
| Current Valuation | 34.88 M | |||
| Shares Outstanding | 697.45 M | |||
| Shares Owned By Insiders | 70.39 % | |||
| Price To Sales | 29.64 X | |||
| Revenue | 952.13 K | |||
| Gross Profit | (512.51 K) | |||
| EBITDA | (1.07 M) | |||
| Net Income | (1.83 M) | |||
| Cash And Equivalents | 20.61 K | |||
| Total Debt | 40 K | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.88 M) | |||
| Beta | 10.61 | |||
| Market Capitalization | 62.47 M | |||
| Total Asset | 3.83 M | |||
| Net Asset | 3.83 M |
About MedMira Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedMira's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedMira using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedMira based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in MedMira Stock
MedMira financial ratios help investors to determine whether MedMira Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedMira with respect to the benefits of owning MedMira security.